Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances
Vaxart Ends Sales Agreement, Halts Stock Offering
Express News | Vaxart: Will Not Incur Any Termination Penalties as Result of Termination
Express News | Vaxart: Provided Notice to Sales Agents to Terminate Sales Agreement, Effective Oct 18
Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer
Oppenheimer Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Sticks to Their Buy Rating for Vaxart (VXRT)
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Express News | Vaxart Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating Its Covid-19 Oral Pill Vaccine Candidate
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart's Pre-clinical Data Reveals Potential Of Mucosal Vaccine Platform For HPV- Cervical Dysplasia
Vaxart Dips on Test Results
Express News | Vaxart- Co's Hpv Vaccine Constructs Can Stimulate Potent Immune Response Against Hpv16 Proteins E6 & E7
Express News | Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
Vaxart, Inc.'s (NASDAQ:VXRT) 39% Share Price Surge Not Quite Adding Up
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
B.Riley Financial analyst Mayank Mamtani maintains $Vaxart(VXRT.US)$ with a buy rating, and maintains the target price at $2.5.According to TipRanks data, the analyst has a success rate of 26.4% and
Vaxart's Promising Vaccine Pipeline: Leading in Mucosal Immunity With Government Support and Competitive Advantages
Oral vaccines have broad prospects. O'Brien, Homer, gives Vaxart (vaxart.US) an 'outperform' rating against the large cap market.
Initiating coverage on Vaxart (VXRT.US) with an outperform rating and target price of $4, which is expected to outperform the overall market.